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Abstract
Objective: Type 2 diabetes (T2DM) and obesity are associated with magnesium deficiency. We aimed to determine whether
the presence of type 2 diabetes and the degree of metabolic control are related to low serum magnesium levels in obese
individuals.
Methods: A) Case-control study: 200 obese subjects [50 with T2DM (cases) and 150 without diabetes (controls)]
prospectively recruited. B) Interventional study: the effect of bariatric surgery on serum magnesium levels was examined in
a subset of 120 obese subjects (40 with type 2 diabetes and 80 without diabetes).
Results: Type 2 diabetic patients showed lower serum magnesium levels [0.7560.07 vs. 0.8160.06 mmol/L; mean difference
20.06 (95% CI 20.09 to 20.04); p,0.001] than non-diabetic patients. Forty-eight percent of diabetic subjects, but only 15%
of non-diabetic subjects showed a serum magnesium concentration lower than 0.75 mmol/L. Significant negative
correlations between magnesium and fasting plasma glucose, HbA1c, HOMA-IR, and BMI were detected. Multiple linear
regression analysis showed that fasting plasma glucose and HbA1c independently predicted serum magnesium. After
bariatric surgery serum magnesium increased only in those patients in whom diabetes was resolved, but remain unchanged
in those who not, without difference in loss weight between groups. Changes in serum magnesium negatively correlated
with changes in fasting plasma glucose and HbA1c. Absolute changes in HbA1c independently predicted magnesium
changes in the multiple linear regression analysis.
Conclusions: Our results provide evidence that the presence of diabetes and the degree of metabolic control are essential
in accounting for the lower levels of magnesium that exist in obese subjects.
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Introduction
Magnesium is the fourth most abundant cation in the human
body and the second most profuse intracellular cation. It is an
important cofactor in a number of key enzymatic reactions and
appears to play an important role in glucose metabolism and insulin
homeostasis. In recent years, increasing evidence has appeared
suggesting an association between magnesium deficiency and type 2
diabetes mellitus (T2DM) [1–5]. In the Atherosclerosis Risk in
Communities Study, Caucasian men with serum magnesium
,0.58 mmol/L had a two-fold increase in incidence of T2DM
compared with those with a magnesium concentration
.0.78 mmol/L [1]. Furthermore, the available data also indicates
that low dietary magnesium intake may be an independent risk
factor for the development of T2DM [1,3]. In this regard, the Health
Professionals Follow-Up Study and the Nurse’s Health Study showed that
subjects in the highest quintile of magnesium intake had a 33%
lower risk of developing T2DM than those in the lowest quintile of
magnesium intake [3]. Finally, magnesium supplementation in
subjects with T2DM resulted in an improvement of insulin
sensitivity and metabolic control [2]. However such findings have
not been reported consistently in other trials [6].
The mechanisms whereby hypomagnesemia may induce or
worsen existing diabetes are not well understood. Nonetheless, it
seems that both insulin secretion and insulin action can be affected
[7]. Alternatively, some studies performed in non-morbidly obese
subjects showed that insulin resistance and chronic hyperglycemia
might contribute to the development of hypomagnesemia [8,9].
Because insulin has been implicated in enhancing renal magne-
sium reabsortion, insulin deficiency or resistance could promote
urinary magnesium excretion [7,10]. Therefore, hypomagnesemia
seems to be a contributing factor for T2DM development but type
2 diabetes could also be involved in low magnesium levels found in
the diabetic population.
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have lower circulating magnesium concentrations than healthy
subjects [11]. However, it is unknown whether the lower levels of
magnesium found in obese subjects are related to the presence of
associated diabetes rather than to obesity itself. Since bariatric
surgery by the Roux-en-Y gastric bypass (RYGBP) is associated
with high percentages of T2DM resolution [12], it represents a
good model for testing the hypothesis that T2DM is the main
factor accounting for the low magnesium levels that exist in obese
patients.
On this basis, the overall aim of this study was to determine
whether the presence of T2DM and the degree of metabolic
control are related to low serum magnesium levels in obese
individuals. To shed light to this issue we performed two types of
studies: 1) A case-control study in order to compare serum
magnesium levels between T2DM and non-diabetic obese subjects
closely matched by BMI, age and gender; 2) An interventional
study in order to elucidate whether those patients in whom the
surgical procedure normalized blood glucose levels also showed a
significant increase in serum magnesium levels.
Materials and Methods
Ethics statement
Informed written consent was obtained from all participants and
the study was approved by the hospital’s human ethics committee
(Hospital Universitari Vall d’Hebron).
Design of the study and description of study population
Cross sectional case-control study. In this study we have
investigated the association between serum magnesium levels and
T2DM in morbidly obese subjects, following the ‘‘Strengthening
the Reporting of Observational Studies in Epidemiology’’
(STROBE) guidelines for reporting case-control studies [13]. We
used the following formula for the sample size calculation:
n~
2 ZazZb ðÞ
2|s2
d2
where the alpha level was set at p,0.05 (Za) and the minimum
acceptable power level was considered to be 0.80 (Zb). s: is the
population standard deviation of serum magnesium in obese
subjects detected in a previous study [14]. d: the postulated effect
size (we considered clinically significant a difference in serum
magnesium between the two groups of 0.04 mmol/L). n: is the
sample size.
n~
21 :96z0:84 ðÞ
2|0:072
0:042 ~48
On this basis, a total of fifty consecutive morbidly obese type 2
diabetic subjects without associated complications attending the
outpatient Obesity Unit of a university hospital (Hospital
Universitari Vall d’Hebro ´n, Barcelona, Spain) were recruited for
the study over a 12-month period (cases). We aimed to select 3
controls for every case and, consequently, one-hundred and fifty
non-diabetic subjects attending the same Obesity Unit served as a
control group. Controls were individually matched to cases by
BMI, age and gender.
None of the participants had a positive clinical history of
malignancy, chronic diarrhea, chronic or acute renal failure,
alcohol intake ($30 g per day), nor abuse of any kind of drug.
Subjects receiving magnesium supplementation or treated with
drugs known to modify magnesium metabolism (such as diuretics,
thyroxine, lithium and/or calcium antagonist) were excluded from
the study. None of the women were pregnant and no patient with
type 1 diabetes was included. According to previous studies,
hypomagnesemia was defined as a serum magnesium concentra-
tion #0.75 mmol/L [5,15,16]. T2DM was defined according to
the criteria recommended by the Expert Committee on the
Diagnosis and Classification of Diabetes.
Interventional study: Surgical induced weight loss
study. The effect of bariatric surgery on serum magnesium
levels was examined in 40 subjects from the type 2 diabetic group
who met the eligibility criteria for gastrointestinal surgery established
by the guidelines of the National Institutes of Health Consensus
Conference. In these patients a RYGBP surgery was performed over
a 18-month period. Briefly, the laparoscopically RYGBP was
performed using 5 trocars placed in a standard fashion for
laparoscopic upper gastrointestinal surgery. Carbon dioxide
pneumoperitoneum (15 mmHg) was created using the Veress
needle technique. A 30-mL gastric pouch was then tailored
around a regular Fouchet tube. To create the jejunojejunostomy,
both the greater omentum and transverse colon were passed to the
upper abdomen, and the jejunum was transected at 60 cm from the
ligament of Treitz. The Roux limb was then measured 150 cm
distally,anda side-to-sideanastomosiswascreatedwiththe proximal
jejunal limb. Finally, the end-to-side gastrojejunostomy was created.
Eighty non-diabetic obese subjects who also underwent RYGBP
surgery during the same period served as a control group. Controls
were individually matched to cases by BMI, age and gender.
After surgery all patients were given the following diet: during the
first ten days, a fluid diet of 810 kcal/day (45% carbohydrates, 33%
protein, and 22% fat); between days 11 and 20, a triturated diet of
839 kcal/day (44% carbohydrates, 38% protein, and 18% fat);
during the last ten days of the first month, a solid diet of 844 kcal/
day (41% carbohydrates, 31% protein, and 28% fat); from the
second months to the end of the study, all patients were placed on a
maintenance diet of 825 kcal (44% carbohydrates, 34% protein,
and 22% fat). No patient received magnesium supplementation.
The exclusion criteria were the same as that above mentioned
for the case-control study. Patients were followed during a 6-
month period and diabetes resolution was defined as the ability to
discontinue all diabetes-related medications and maintain blood
glucose and HbA1c levels within the normal range (#5.5 mmol/L
and #6.0%, respectively) [12]. Blood samples for general analyses
and magnesium measurements were drawn at baseline 3 and 6
months after surgery.
Laboratory assessment
All laboratory measurements were performed on fasting blood
samples. Serum magnesium was measured by spectrophotomet-
rical xylidyl blue method on Olympus AU2700 analyser using its
own commercial kit (Olympus Diagnostics GmBH, Hamburg,
Germany). The principle of the method depends on the formation
of colored complex between magnesium ions with xylidyl blue in
an alkaline medium. The laboratory coefficient of variation for
magnesium, based on split samples, was 1.9%. Other biochemical
parameters analyzed included measurement of plasma glucose,
insulin, and HbA1c. These parameters were measured by
standard laboratory techniques used in clinical chemistry labora-
tories. Insulin resistance was determined by the homeostasis model
assessment [HOMA-IR=insulin (mU/L)6glucose (mmol/L)/
22.5)]. HOMA-IR was restricted to individuals no currently
taking antidiabetic drugs. Finally, serum 25-hydroxy vitamin D
[25(OH)D] and intact parathyroid hormone (iPTH) were
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say (CLIA) (DiaSorin Inc., Stillwater, MN, USA) using the
LIAISON Analyzer family. The means intra and interassay
coefficient of variation for 25(OH)D were 4.5% and 7.6%
respectively. The means intra and interassay coefficient of
variation for iPTH were 3.8% and 7.9% respectively.
Statistical analysis
Normal distribution of the variables was evaluated using the
Kolmogorov-Smirnov test. Data were expressed either as the mean
6 SD, median (range), or percentage. Given their skewed
distribution, HOMA-IR data was logarithmically transformed to
achieve a normal distribution. Comparisons between groups were
performed using the unpaired Student t test for continuous
variables, and the x
2 test for categorical variables. The change of
the variables compared with the baseline values were used for the
analysis of treatment (bariatric surgery) effect for each group using
Student-t test for paired data. The relationship between continuous
variables was examined by the Pearson linear correlation test.
In the cross sectional case-control study a stepwise multiple
linear regression analysis was performed in order to explore the
variables independently related to serum magnesium. The
variables included were age, BMI, fasting plasma glucose, HbA1c,
and HOMA-IR. In the interventional study, a new stepwise
multiple linear regression analysis was performed in order to
explore the variables independently related to the absolute change
of serum magnesium at 6 months. The variables included were
BMI, age, and absolute changes in fasting plasma glucose and
HbA1c.
All p values were based on a two-sided test of statistical
significance. Significance was accepted at the level of p,0.05.
Statistical analyses were performed with the SSPS statistical
package (SPSS Inc, Chicago, Illinois).
Results
Cross sectional case-control study
The main clinical features and laboratory data of the study
population according to the presence of T2DM are presented in
Table 1. Diabetic patients showed lower serum magnesium
concentrations in comparison with non-diabetic patients
[0.7560.07 vs. 0.8160.06 mmol/L; mean difference 20.06
(95% CI 20.09 to 20.04); p,0.001]. Forty-eight percent of
diabetic subjects showed a serum magnesium concentration lower
than 0.75 mmol/L, but only fifteen percent of non-diabetic
subjects (p,0.001) did so.
Univariate analysis showed that in the whole population, as well
as in diabetic patients, serum magnesium negatively correlated
with fasting plasma glucose (r=20.443, p,0.001 and r=20.484,
p,0.001, respectively) and HbA1c (r=20.470, p,0.001 and
r=20.389, p=0.010, respectively) (Figure 1). By contrast, the
negative correlation observed between serum magnesium and
both HOMA-IR (r=20.182, p=0.015) and BMI (r=20.142,
p=0.046) disappeared when type 2 diabetic subjects were
analyzed separately (r=20.101, p=0.525 and r=20.231,
p=0.106, respectively).
Multiple linear regression analyses showed that both HbA1c (in
the whole population) and fasting plasma glucose (in type 2
diabetic subjects) were independently related to serum magnesium
(Table S1).
Interventional study: Surgical induced weight loss study
The subset of 120 subjects who underwent RYGBP showed
similar baseline characteristics to those observed in the entire
population (Table 2). Diabetic patients showed lower serum
magnesium concentrations than non-diabetic patients [0.7760.07
vs. 0.8260.07 mmol/L; mean difference 20.04 (95% CI 20.08 to
20.02); p=0.001].
Three months after RYGBP, serum magnesium had signifi-
cantly increased in those patients in whom diabetes was resolved
[0.7860.07 vs. 0.8360.05 mmol/L; mean difference 0.05 (95%
CI 0.02 to 0.08); p=0.001] (Table 3). By contrast no significant
changes were observed in those patients in whom diabetes was
unresolved or in those non-diabetic obese subjects. This effect can
not be attributed to weight loss because excess body weight loss
(EBWL) was the same in both groups. These findings were
maintained in the analyses performed at 6 months of follow-up
(Table 3). In addition, no significant differences in baseline serum
Table 1. The main clinical features and laboratory data of the study population from the cross sectional case-control study
according to the presence of type 2 diabetes.
Type 2 Diabetes Non-diabetic Mean difference (95%CI) p
n 50 150 - -
Women, n (%) 40 (80.0) 114 (76.0) - 0.355
Age (years) 45.0668.59 44.7168.25 0.35 (22.33 to 3.04) 0.796
BMI (Kg/m
2) 46.4565.87 46.3065.46 0.15 (21.60 to 1.94) 0.869
Mg (mmol/L) 0.7560.07 0.8160.06 20.06 (20.09 to 20.04) ,0.001
Mg#0.75 mmol/L, n (%) 24 (48.00) 23 (15.33) - ,0.001
Fasting plasma glucose (mmol/L) 8.7363.47 5.6061.16 3.12 (2.12 to 4.13) ,0.001
HbA1c (%) 7.6061.87 5.7660.56 1.84 (1.25 to 2.43) ,0.001
Fasting insulin (mU/L) 23.40612.65 19.76611.43 3.64 (20.44 to 7.72) 0.080
HOMA-IR* 8.04 (0.84–38.88) 4.26 (0.93–23.46) - ,0.001
25(OH)D (nmol/L) 46.05623.92 47.85625.05 21.80 (210.62 to 7.02) 0.688
iPTH (ng/mL) 67.06628.29 69.45622.30 22.39 (212.50 to 7.72) 0.640
Data are mean 6 SD, median (range), and percentage. Mg: serum magnesium; BMI: body mass index; HOMA-IR: insulin resistance measured by the homeostasis model
assessment; 25(OH)D: 25-hydroxy vitamin D; iPTH: intact parathyroid hormone.
*: Restricted to individuals without current hypoglycaemic medication.
doi:10.1371/journal.pone.0030599.t001
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sectional case-control study. White circles, non-diabetic patients (fasting plasma glucose: r=20.155, p=0.059; HbA1c: r=20.302, p=0.002);
black circles, type 2 diabetic patients (fasting plasma glucose: r=20.484, p,0.001; HbA1c: r=20.389, p=0.010).
doi:10.1371/journal.pone.0030599.g001
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patients who resolved and not-resolved their diabetes after 6
month of follow up [0.7860.06 vs. 0.7460.09 mmol/L; mean
difference 0.03 (20.01 to 0.09); p=0.152].
Multiple linear regression analyses showed both in the whole
population as in the subgroup of diabetic subjects that absolute
changes in HbA1c were independently related to serum
magnesium changes at 6 months, and explained 24.7% and
23.2% of the magnesium variation, respectively (Table S2).
No differences in iPTH between patients who resolved and did
not resolve their diabetes were observed after 3-months and 6
months of follow-up (80.42635.56 vs. 80.99624.05 ng/mL,
p=0.956, and 86.99644.33 vs. 93.86627.18 ng/mL, p=0.604;
respectively). In addition, no correlation between serum magne-
sium and iPTH was observed at 3-months (r=0.070, p=0.500) or
6-months (r=20.034, p=0.755) after RYGBP. Similarly, no
differences in 25(OH)D between patients who resolved or did not
resolve their diabetes were observed after 3-months (46.02625.67
vs. 52.42621.60 nmol/L, p=0.425) or 6-months (37.77620.92 vs.
33.67617.3 nmol/L, p=0.529) of follow-up. Moreover, no
correlation between serum magnesium and 25(OH)D was
observed at 3-months (r=0.020, p=0.831) or 6-months
(r=0.128, p=0.195) after bariatric surgery.
Two non-diabetic patients required early reoperation for
treatment of gastrointestinal leak at the vertical staple-line portion
of the gastric pouch. Two more patients (one diabetic and one
non-diabetic subject) suffered recurring nausea and vomiting,
without evidence of stomal stenosis, which resolved spontaneously
after the second month of follow-up. No patient suffered from
diarrhoea.
Discussion
In the present study we provide first evidence that T2DM is the
main factor accounting for the low serum magnesium levels found
in morbidly obese subjects. In fact, the percentage of subjects with
a serum magnesium concentration lower than 0.75 mmol/L was
three fold higher in diabetic patients in comparison with non-
Table 2. The main clinical features and laboratory data of the study population underwent RYGBP according to the presence of
type 2 diabetes.
Type 2 Diabetes Non-diabetic Mean difference (95%CI) p
n 40 80 - -
Women, n (%) 30 (75.0) 62 (77.5) - 0.820
Age (years) 45.7868.62 45.1868.36 0.60 (22.64 to 3.84) 0.714
BMI (Kg/m
2) 45.7566.01 46.0965.18 20.33 (22.43 to 1.76) 0.751
Magnesium (mmol/L) 0.7760.07 0.8260.07 20.04 (20.08 to 20.02) 0.001
Mg#0.75 mmol/L, n (%) 18 (45.00) 14 (17.5) - 0.006
Fasting plasma glucose (mmol/L) 8.9663.61 5.7461.19 3.21 (2.03 to 4.39) ,0.001
HbA1c (%) 7.9961.82 5.8160.61 2.17 (1.50 to 2.84) ,0.001
Fasting insulin (mU/L) 23.98614.84 19.0969.32 4.89 (21.55 to 11.32) 0.131
HOMA-IR* 7.23 (2.24–38.88) 4.22 (1.17–13.85) - 0.005
25(OH)D (nmol/L) 52.35635.65 52.10626.90 0.02 (212.45 to 12.92) 0.971
iPTH (ng/mL) 65.44628.32 70.38623.03 24.94 (216.28 to 6.38) 0.388
Data are mean 6 SD, median (range), and percentage. Mg: serum magnesium; BMI: body mass index; HOMA-IR: insulin resistance measured by the homeostasis model
assessment; 25(OH)D: 25-hydroxy vitamin D; iPTH: intact parathyroid hormone.
*: Restricted to individuals without current hypoglycaemic medication.
doi:10.1371/journal.pone.0030599.t002
Table 3. Three and 6-months evolution after RYGBP of serum magnesium concentrations in non-diabetic subjects, and both type
2 diabetic obese patients who resolve and not resolve their diabetes.
Baseline magnesium
(mmol/L)
Follow-up magnesium
(mmol/L) p
3-months
T2D resolved (n=21) 0.7860.07 0.8360.05 0.001
T2D not resolved (n=19) 0.7660.09 0.7860.09 0.136
Non diabetic (n=80) 0.8260.07 0.8060.06 0.456
6-months
T2D resolved (n=25) 0.7760.06 0.8360.04 ,0.001
T2D not resolved (n=15) 0.7760.09 0.8160.07 0.116
Non diabetic (n=80) 0.8260.07 0.8260.07 0.931
No differences in EBWL (excess body weight loss) was observed between type 2 diabetic subjects who resolved and not resolved their diabetes at 3-months
(38.3968.10 vs. 35.38614.69%, p=0.480), nor 6-months (50.87612.05 vs. 48.77617.27%; p=0.687) of follow up.
doi:10.1371/journal.pone.0030599.t003
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found a relationship between the degree of blood glucose control
(fasting plasma glucose and HbA1c) and magnesium serum
concentration, and fasting plasma glucose and HbA1c were
independently related to magnesium concentration in multiple
linear regression analysis. Furthermore, in the subset of patients who
underwent bariatric surgery, serum magnesium increased only in
type 2 diabetic subjects in whom diabetes was resolved, but remain
unchanged in whom it wasn’t as well as in non-diabetic subjects.
Finally, absolute changes in HbA1c, but not changes in weight loss,
independentlypredicted changesinserum magnesiumafter bariatric
surgery. Taken together, these findings suggest that the lower levels
of magnesium reported in obese subjects are related to the presence
of diabetes and glycemic control rather than obesity itself.
The magnesium homeostasis is tightly regulated and depends on
the balance between intestinal absorption and renal excretion
[16]. In addition, genetic determinants and sex hormones can also
modulate serum magnesium levels [17–21]. The mechanisms by
which T2DM could lead to low serum magnesium levels remain to
be fully understood. It has been suggested that it may result from
enhanced renal magnesium excretion. Because insulin has been
related to magnesium reabsortion at the thick ascending limb of
the loop of Henle, insulin deficiency or resistance can promote
magnesium wasting at this nephron segment [7,10]. In addition,
hyperglycemia and glycosuria may also interfere with renal
magnesium handling, mainly by reducing the tubular reabsorption
of the cation. In this regard, McNair et al showed that
hypermagnesiuria occurred in 55% of insulin-treated diabetic
out-patients, and correlated inversely with fasting blood glucose
and the urinary glucose excretion rate [22]. Thus, although
magnesium excretion was not measured in the present study, an
increased urinary magnesium loss could be invoked to explain the
low concentration of serum magnesium observed in morbidly
obese patients with T2DM. Other potential causes of lower serum
magnesium in obese type 2 diabetic patients include reduced
intestinal magnesium absorption secondary to higher fat intake
and lower fiber intake [23,24], and diabetic autonomic neurop-
athy that may reduce oral intake and gastrointestinal absorption
[7,10]. However, a significant role of these mechanisms in
accounting for the difference in serum magnesium concentration
between diabetic and non-diabetic patients included in the present
study is very unlikely. Insulin may induce a shift of magnesium
from the plasma to the erythrocytes and smooth muscle cells, both
in vivo and in vitro, helping to explain the abnormalities in
magnesium circulating levels frequently reported in diabetic
patients [25]. However, the lack of difference in serum magnesium
levels between type 2 diabetic patients treated with insulin or oral
agents suggests that this is not a relevant mechanism, at least in the
patients included in the present study.
Low circulating magnesium levels have been related to elevated
blood pressure, atherogenic dyslipidemia, impaired clotting,
increased inflammatory burden, oxidative stress, carotid wall
thickness and coronary heart disease [26,27]. Therefore, hypomag-
nesemia could be considered an additional source of cardiovascular
riskinT2DM. In addition, hypomagnesemia has been implicated in
adversely affecting diabetic complications [28,29]. Furthermore, it
has recently been shown that low serum magnesium concentrations
increase the risk of all-cause mortality in T2DM [30]. Obviously,
the presence of obesity might increase cardiovascular risk and the
mortality rate associated with low magnesium levels.
Apart from diabetic complications and the mortality rate,
hypomagnesemia could influence both insulin secretion and
insulin action. In this regard it has been suggested that reduced
intracellular magnesium concentrations result in an altered cellular
glucose transport, a defective tyrosine-kinase activity, post-receptor
impairment in insulin action by influencing intracellular signaling
and processing, and reduced pancreatic insulin secretion [7,31]. In
addition, chronic magnesium deficiency has also been associated
with elevated concentrations of TNF-alpha, and this fact may also
contribute to post-receptor insulin resistance [32]. Therefore,
T2DM could facilitate low serum magnesium levels and this could
in turn worsen glycemic control of diabetes, thus establishing a
vicious circle that could lead to a progressive impairment in
metabolic control and more risk of diabetic complications. Our
results suggest that this vicious circle could be broken by the
optimization of metabolic control. In addition, as cereal fiber and
magnesium intake have been associated with a reduced risk of
T2DM independent of age, sex, and lifestyle risk factors, it also
seems prudent to recommend an increased consumption of
magnesium-rich foods such as whole grains, beans, nuts and
green leafy vegetables in patients with diabetes mellitus who have
proven hypomagnesemia [24,33].
The close relationship between hypomagnesemia and T2DM is
reinforced when the evolution of both disorders is evaluated after
surgical mediated weight loss. In the present study we provide first
evidence that only obese patients who resolved T2DM through the
RYGBP achieved a progressive normalization of serum magnesium
concentrations. These results can not be attributed to magnesium
biological variation and/or analytical imprecision [34]. In addition,
we have found that changes in serum magnesium inversely
correlated with decreases in both fasting plasma glucose and
HbA1c. In addition, absolute changes in HbA1c contributed
independently to magnesium changes in multiple linear regression
analysis both in the whole population as in diabetic patients,
suggesting that metabolic improvement after bariatric surgery is
clearly involved in these changes. Limited data about the evolution
of serum magnesium after bariatric surgery exist. Although
malabsorptive procedures give rise to severe hypomagnesemia,
Johansson et al have recently communicated an increase in
magnesium concentration in non-diabetic morbidly obese patients
who underwent RYGBP [14]. This data is in accordance with our
results, where serum magnesium concentrations in non-diabetic
subjects also increased, but in a smaller magnitude than in diabetic
patients. Given that both iPTH and 25(OH)D influence serum
magnesium levels, these parameters should be taken into account in
the analysis of the results. In this regard serum levels of iPTH and
25(OH)D were closely similar during follow-up in patients in whom
diabetes was resolved in comparison with those in whom diabetes
was not resolved. In addition, we did not find any correlation
between either iPTH or 25(OH)D and serum magnesium levels.
There are some potential limitations that should be taken into
account in evaluating the results of our study. First, we did not
measure intracellular magnesium content, a more sensitive indicator
of magnesium balance [35]. Nevertheless, although approximately
only 1% of whole-body magnesium is found extracellularly, serum
magnesium exhibits a good correlation withintracellularmagnesium
measuredbynuclearmagneticresonancespectroscopy[36].Second,
we have not specifically evaluated dietary magnesium daily intake.
However, given that subjects receiving magnesium supplementation
were carefully excluded this possibility is very unlikely. In addition,
the same diet was indicated in the subset of patients who underwent
bariatric surgery. Finally, only a selected population of morbidly
obese subjects was included. Although our results and the possible
mechanisms involved in the negative effect of T2DM on magnesium
levels might also be transferable to less obese individuals, further
studies in these populations are required.
In conclusion, diabetes is the main factor accounting for the low
serum magnesium levels found in morbidly obese subjects and it is
Magnesium and Diabetes
PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e30599clearly related to the degree of glycaemic control. Since low serum
magnesium levels are an independent cardiovascular risk factor
and favour diabetic complications, the normalization of serum
magnesium levels is another good reason to recommending the
optimization of blood glucose in T2DM.
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